BIND CEO Says Amgen Deal Marks Nanomedicine Turning Point

1/9/13Follow @cathyarnst

(Page 2 of 3)

at Harvard Medical School. The company is using the two professors’ method for developing highly targeted drugs for cancer and other diseases based on nano-sized particles, which BIND has named Accurins.

These microscopic particles are meant to ferry chemotherapies and other treatments directly to diseased cells while avoiding healthy ones. The idea is that the particles are so tiny that they can evade detection by the immune system, but then accumulate at the diseased cell and achieve higher drug concentrations than would be possible with a larger molecule.

BIND’s research is currently supported in part by the MIT-Harvard Center for Cancer Nanotechnology, which in turn is part of a $144 million investment by the National Cancer Institute in nanotechnology research. It also has $25 million in funding from Rusnano, … Next Page »

Single Page Currently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.